Skip to main content
. 2022 Jul 19;28(18):3965–3978. doi: 10.1158/1078-0432.CCR-22-0803

Figure 2.

Figure 2. Somatic TP53, PTEN, and PDGFRA alterations are associated with clinical outcomes in H3K27-altered DIPG. A, Oncoprint representation of recurrent somatic driver gene alterations in H3K27-altered DIPGs with available WES, WGS, and mRNA-seq, regardless of the availability of survival outcomes (n = 30). H3K27-altered DIPG subtyping based on the 2021 WHO Classification of Central Nervous System Tumors system: H3F3A (p.K27M), HIST1H3B (p.K27M), and EZHIP overexpression. B, Association between somatic driver gene status and OS in H3K27-altered DIPG patients (n = 28). Lollipop plot shows the −log10 log-rank test P value for all tested driver genes (n = 8). Red colored dots mark genes significantly (P < 0.05) associated with OS. C–E, Kaplan–Meier survival curves and log-rank P values for H3K27-altered DIPG patients stratified by TP53 (C), PDGFRA (D), and PTEN (E) alteration status. WES, whole-exome sequencing; WGS, whole-genome sequencing; mRNA-seq, mRNA sequencing; OS, overall survival; PFS, progression-free survival; wt, wild-type; mut, mutant; amp, amplification.

Somatic TP53, PTEN, and PDGFRA alterations are associated with clinical outcomes in H3K27-altered DIPG. A, Oncoprint representation of recurrent somatic driver gene alterations in H3K27-altered DIPGs with available WES, WGS, and mRNA-seq, regardless of the availability of survival outcomes (n = 30). H3K27-altered DIPG subtyping based on the 2021 WHO Classification of Central Nervous System Tumors system: H3F3A (p.K27M), HIST1H3B (p.K27M), and EZHIP overexpression. B, Association between somatic driver gene status and OS in H3K27-altered DIPG patients (n = 28). Lollipop plot shows the −log10 log-rank test P value for all tested driver genes (n = 8). Red colored dots mark genes significantly (P < 0.05) associated with OS. C–E, Kaplan–Meier survival curves and log-rank P values for H3K27-altered DIPG patients stratified by TP53 (C), PDGFRA (D), and PTEN (E) alteration status. WES, whole-exome sequencing; WGS, whole-genome sequencing; mRNA-seq, mRNA sequencing; OS, overall survival; PFS, progression-free survival; wt, wild-type; mut, mutant; amp, amplification.